Efficacy and safety of BioBoost supplement on the incidence of COVID-19 symptoms of asymptomatic family members of COVID-19 patients

Phase 3

Conditions: COVID-19.
COVID-19, virus identified
U07.1

Registration Number: IRCT20200318046812N3

Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 500

Inclusion Criteria

Confirmation of infection by PCR in a family member
Informed written consent
Living in Tehran
Number of family members between 2 and 5
Age between 18 to 63 years
No prognostic signs of Covid-19 disease two weeks before enrollment

Exclusion Criteria

Not participating in another clinical trial in the last three months
Do not use other supplements (containing vitamins, minerals, and probiotics)
No documented history of Covid-19 infection in healthy family members
Pregnancy / breastfeeding
Drug sensitivity to the compounds in the intervention
Temporary residence or immigration and consecutive relocation from Tehran
Use similar supplements

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
?S?everity of cough. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone followup.;?Severity of shortness of breath. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone followup.

Secondary Outcome Measures

Name	Time	Method
Preentation of fever, headache, .. as a Yes/ no. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.;Recording the severity of symptoms by comparing Likert from a score of 1 to 10. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.;The duration of symptoms and duration of hospitalization based on the date of onset and date of remission. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.